Omnio Healer Selects Eden Biodesign for cGMP Production of its Candidate Wound Healing and Anti-Infection Treatments

Friday, September 18, 2009 General News
Email Print This Page Comment
Font : A-A+

UMEA, Sweden, August 6 Omnio Healer AB, a pioneer companydeveloping novel therapies for wound healing and anti-infection, todayannounced that it has entered into a partnership agreement with EdenBiodesign. Under the agreement Eden Biodesign will provide processdevelopment and cGMP production services relating to Omnio Healer's leadrecombinant protein candidate.

Based on a novel therapeutic concept for wound healing andanti-infection, Omnio Healer is developing drug candidates with potentpro-inflammatory functions. The agreement with Eden Biodesign relates to theexpression of proteins using mammalian cell culture for use against severalclinical indications, but primarily for studies relating to chronic eardrumwounds.

Omnio Healer selected Eden Biodesign as its preferred manufacturingpartner after an extensive due diligence exercise that evaluated numerouscontract manufacturing organizations in both Europe and the United States.Eden Biodesign will undertake the development of a robust manufacturingprocess for the product leading to cGMP production for supplying clinicalstudies. Omnio Healer has also assessed Eden Biodesign as a potential futurecommercial manufacturer of the product using Eden's MHRA-inspectedstate-of-the-art cGMP manufacturing facilities located in Liverpool, UK.

Mats Stromqvist, CEO of Omnio Healer AB, said, "Our protein product hasshown very promising preclinical results in wound healing indications. We arenow very keen to take the next step and gain access to GMP-material for usein clinical trials. At the same time, we have every confidence that EdenBiodesign will become a valuable partner in this regard, providing both cGMPprocess development and production."

Eden Biodesign's CEO, Dr. Crawford Brown, commented, "We are extremelyhappy to have been selected by Omnio Healer to support the development ofthis important product. Based on our extensive experience, industry expertiseand first class facilities we hope to be able to add considerable value andflexibility to Omnio Healer's development program."

About Omnio Healer

Omnio Healer AB is a pioneer company developing novel drug candidatesbased on a series of conceptual breakthroughs in inflammation research. Thisnew, pro-inflammatory approach opens up completely new therapeutic strategiesfor wound healing and anti-infection. The company's lead drug candidate,aimed primarily at otological indications, has achieved very promisingpreclinical results and will enter a clinical development program in late2010.

Since its foundation in 2006 Omnio Healer has assembled a strongmanagement and development team. This includes world-renowned scientistswithin the field, experienced product development professionals and activeinvestors led by Karolinska Development AB, providing access to a highlyqualified network of biotechnology development resources. The company isbased in Umea, Sweden. Find out more at http://www.omniohealer.com.

About Eden Biodesign

Eden Biodesign is a globally-integrated biopharmaceutical companyoffering consultancy, biopharmaceutical design and cGMP manufacturingservices to leading biotech and pharmaceutical clients around the world. Witha reputation for successfully commercializing biopharmaceutical products andprocesses, the company offers expertise and guidance in multiple sectors.Eden's world-class facilities and knowledge in process development,manufacturing, regulatory and technology transfer support ensure that EdenBiodesign offers much more than a traditional CMO. Find out more athttp://www.EdenBiodesign.com.For more information, contact: Omnio Healer AB Mats Stromqvist, PhD, Professor, CEO Omnio Healer AB Tel. +46-70-631-0035 info@omniohealer.com Eden Biodesign John D. Wagner, Propel Marketing Group Tel. +44-919-796-9984 Jdwagner@PropelMG.com http://www.PropelMG.com

SOURCE Omnio Healer AB


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook